Menu
← Oncology Approval Tracker
FDA DECISION ·
Imfinzi + Padcev
durvalumab and enfortumab vedotin-ejfv · AstraZeneca (Imfinzi)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Neoadjuvant durvalumab with enfortumab vedotin-ejfv, followed after radical cystectomy by adjuvant durvalumab alone, for adults with muscle-invasive bladder cancer who cannot receive or have refused cisplatin-based chemotherapy.
SUPPORTING DATA
Evidence behind the decision
- Study
- VOLGA: randomized, open-label, three-arm trial enrolling 695 surgical candidates.
- Key result
- Against cystectomy alone, event-free survival hazard ratio was 0.51 (95% CI 0.38-0.67); overall-survival hazard ratio was 0.58 (95% CI 0.40-0.83).
- Safety to report
- FDA highlights immune-mediated toxicity, infusion reactions, rash, laboratory abnormalities and peripheral neuropathy.
- Evidence limits
- The comparator was surgery alone, not another approved perioperative drug regimen. These findings do not establish superiority over that regimen.
LAMPGEN ANALYSIS
Why it matters
Adds a perioperative option for the specified cisplatin population. Eligibility and postoperative treatment differ from other approved bladder regimens.
What research teams should watch
Coordinate screening, cisplatin eligibility or refusal documentation, surgery scheduling, perioperative assessments and postoperative handoffs.
PRIMARY RECORDS